Brought to you by 
Alexion takes $25mm stake in Moderna and options on messenger RNA Therapeutics; terminated
27 Jul 2017
Executive Summary
In its second major deal in less than a year, start-up Moderna Therapeutics Inc. licensed Alexion Pharmaceuticals Inc. (ultra-rare disorders) ten exclusive worldwide options to messenger RNA Therapeutics for rare diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com